Keywords: |
cancer survival; treatment response; cancer surgery; salvage therapy; cisplatin; cancer combination chemotherapy; drug efficacy; drug withdrawal; unspecified side effect; paclitaxel; cancer patient; disease free survival; drug megadose; carboplatin; multiple cycle treatment; neoplasm recurrence, local; etoposide; antineoplastic combined chemotherapy protocols; editorial; drug resistance, neoplasm; ifosfamide; testicular neoplasms; stem cell mobilization; neoplasms, germ cell and embryonal; germ cell tumor; granulocyte colony stimulating factor; seminoma; drug indication
|